Math-free guides for glycerin and allergens at variable subcutaneous injection volumes: How’s my dosing? Update.

Related Articles

Math-free guides for glycerin and allergens at variable subcutaneous injection volumes: How’s my dosing? Update.

Ann Allergy Asthma Immunol. 2016 Mar 24;

Authors: Grier TJ, Converse LM, Rekkerth DJ, Renahan KE

Abstract
BACKGROUND: Current summaries of effective maintenance dose ranges for subcutaneous immunotherapy (SCIT) are based on administration of 0.5-mL volumes. Extract formulations delivering equivalent dose ranges for practices using different injection volumes have not been reported, and calculation of the final glycerin concentrations in these solutions remains an inconvenient and repetitive process.
OBJECTIVES: To create math-free guides for allergen doses and glycerin concentrations that identify the extract concentrate volumes required to deliver doses within the ranges cited in the 2011 immunotherapy practice parameters for clinicians using 5.0-mL maintenance vials and injection volumes ranging from 0.2 to 1.0 mL.
METHODS: Algebraic calculations were performed to determine the specific combinations of extract concentrate strengths, volumes of these products in patient vaccines, and injection volumes needed for administration of target allergen doses spanning the current SCIT practice parameter recommendations.
RESULTS: For each product or group (nonstandardized extracts), tables were constructed to define the allergen doses provided by various combinations of extract concentrate volumes and injection volumes. The values within the effective dose ranges for each product were highlighted to facilitate comparisons of specific conditions relevant to allergy specialists. Glycerin tables were also created to permit convenient assessments of the final concentrations of this stabilizer in patient prescriptions.
CONCLUSIONS: SCIT dosing and glycerin tables are useful tools to assist allergists with practice decisions that involve variable patient formulas and injection volumes and can help identify suitable conditions for treatment of patients presenting with diverse allergen sensitivities and specificity profiles.

PMID: 27017565 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Budesonide Inhalation Aerosol (PT008) Dose 1;   Drug: Budesonide Inhalation Aerosol (PT008) Dose 2;   Drug: Budesonide Inhalation Aerosol (PT008) Dose 3;   Drug: Budesonide Inhalation Aerosol (PT008) Dose 4;   Drug: Placebo
Sponsor:   Pearl Therapeutics, Inc.
Not yet recruiting – verified April 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will … – MarketWatch (press release)

Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will
MarketWatch (press release)
The findings from the Pharmacor topic entitled Asthma reveal that Relovair will emerge as the market leader among once-daily LABA/ICS combinations as GlaxoSmithKline wages an aggressive campaign to switch patients off of Advair/Seretide/Adoair prior to

and more »

View full post on asthma – Google News

Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will … – Benzinga

Emerging Asthma Agents That Offer the Convenience of Once-Daily Dosing Will
Benzinga
The findings from the Pharmacor topic entitled Asthma reveal that Relovair will emerge as the market leader among once-daily LABA/ICS combinations as GlaxoSmithKline wages an aggressive campaign to switch patients off of Advair/Seretide/Adoair prior to

and more »

View full post on asthma – Google News